GemVax Pancreatic Cancer Vaccine Set For First Launch, By Samsung
This article was originally published in PharmAsia News
Executive Summary
Despite an earlier Phase III setback for its therapeutic pancreatic cancer vaccine Riavax, GemVax & KAEL Co. has signed a new licensing deal with Samsung Pharm under which the latter will handle manufacturing, supplying and commercializing of the first-in-class product in South Korea.
You may also be interested in...
Medifron Move Signals Alzheimer’s R&D Acceleration In Korea
Medifron DBT's plan to make a sizable investment in its Alzheimer’s disease drug pipelines may be followed by further South Korean biotechs and pharmas accelerating development in the field as the country steps up support for dementia R&D.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.